| Name | Title | Contact Details |
|---|
At Oerth Bio™, we are on a mission to change perceptions of agricultural chemistry We are leading a new and transformative approach to crop protection, crop health and healthy food by leveraging our proprietary PROTAC® protein degraders, or proteolysis-targeting chimeras. PROTAC protein degraders work by harnessing the plant`s own natural protein disposal system to degrade and remove unwanted proteins. We are an early-stage agriculture biotechnology company located in the heart of downtown Durham, North Carolina.
Vantage BioTrials Inc. is a Dollard-Des-Ormeaux, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We Are The Immune System Company™ In 1998, Founders David and Bianca Lisonbee embarked on a journey to bring 4Life Transfer Factor® products to the world. Everything we do at 4Life is guided by our 4 Values: Science, Success, Service, and Satisfaction.
The Ohio State University Medical Center (OSUMC) is a multidisciplinary academic medical center located in Columbus, Ohio
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.